First person cured of type 1 diabetes thanks to stem cells – Freethink

Brian Shelton wept.

He checked his blood sugar, ate a meal with his ex-wife, checked his blood sugar again, and wept.

His insulin levels were perfect. The type 1 diabetes that had caused him to crash his motorcycle, faint in a yard, and forced him to retire from the postal service, was gone.

The diabetes cure was an infusion of stem cells that turned into the type of cells the body needs to produce insulin cells that had never worked in his life before.

Its a whole new life, Shelton told the New York Times Gina Kolata. Its like a miracle.

In just the year before Sheltons treatment, he had suffered five severe, potentially life-threatening episodes of low blood sugar, USA Today reported.

Now, Sheltons dramatic results have those in the field cautiously optimistic that Sheltons stem cell-based procedure could be a cure for diabetes.

The dramatic results have those in the field cautiously optimistic that stem cell-based procedures could be a cure for type 1 diabetes.

Type 1 diabetes: Diabetes comes in two varieties that lead to the same problem: the body cannot keep its blood sugar levels in the right place. In the case of type 2 diabetes, the most common form of the disease, the body does not utilize insulin correctly.

In the case of type 1 diabetes, like Shelton had, the body is wholly missing the cells that create insulin. Called islet cells and found in the pancreas, type 1 diabetes appears to be caused by the immune system wiping them out.

Type 1 diabetes can prove lethal in short order if patients do not receive injections of insulin, and it can cause amputation, kidney transplants, and blindness.

Artificial insulin is the standard treatment, but it can be extremely expensive, and artificial pancreases which have now been approved for children can make managing the condition easier, but are not a cure for diabetes.

There is a known type 1 diabetes cure: transplanting islet cells from a donors pancreas, or the whole pancreas. But it is far from practical there just arent enough healthy, donated pancreases out there.

Which is why Sheltons stem cell results have researchers optimistic but guarded.

It is a remarkable result, UCLA diabetes expert Peter Butler, who was not involved in the trial, told Kolata. To be able to reverse diabetes by giving them back the cells they are missing is comparable to the miracle when insulin was first available 100 years ago.

To develop the treatment, researchers had to reverse-engineer how the body grows the pancreas to begin with.

A dad vs. diabetes: The stem cell treatment Shelton received this past June is the result of decades of work by biologist Doug Melton, who began work on a cure after his kids developed type 1 diabetes.

Melton looked to embryonic stem cells as a potential diabetes cure. Stem cells have the capability to become any kind of cell including islet cells. But coaxing them to become functional insulin-producing cells took decades of trial and error.

Meltons small team had to figure out which chemical signals, in what order, work to create islet cells, Kolata explains; in essence, they needed to reverse-engineer how the body grows the pancreas to begin with.

In 2014, they found it: their stem cell-derived islet cells began producing insulin. They worked as a diabetes cure in rodents. After his company was acquired by Vertex Pharmaceuticals, it was time for the next step: human trials.

Shelton was patient number one.

A cure with a cost: Shelton was infused with the cells, which soon went to work producing insulin and regulating his blood sugar, curing his diabetes. While the results are exciting, aside from the fact its only one patient so far, its not a silver bullet.

Chief among the concerns is rejection. Just like in an organ transplant, an infusion of embryonic stem cells means Shelton needs to take immune system-suppressing drugs to ensure his body doesnt attack the foreign cells. Shelton told Kolata the immunosuppressive regimen causes him no issues, so far, and its much easier to deal with than not making insulin, but it is something to keep an eye on.

Vertex is also looking to run future studies using our encapsulated islet cells, which hold the potential to be used without the need for immunosuppression, Bastiano Sanna, executive VP, said.

The success of a similar technique in Canada is a sign of hope that an outright cure for diabetes may be coming soon.

The study Shelton is involved in is on-going, taking place over five years and enrolling an estimated 17 patients; according to their study listing, Vertex does not expect to complete the study until 2028.

Experts told Kolata that they want to see the results of the trial thus far, which has not yet been peer-reviewed and published. Only further research will suss out if adverse events may arise, or if the treatment is temporary.

Not alone: Sheltons news comes as a team at the University of British Columbia has announced similar promising results, GEN reports.

Patients in the Canadian study, which has been published in Cells Stem Cell journal, used a different type of stem cell, surgically implanted on small, credit-card thick devices.

Our findings demonstrate the incredible potential of this stem cell-based treatment. With further research, this treatment could one day eliminate dependence on insulin injections and transform the management of Type 1 diabetes, UBC professor Timothy Kieffer, the study lead author, said.

While the UBC patients did not produce enough insulin to eliminate their need for it, the follow up period, which lasted up to a year, found that their insulin requirements had decreased by 20%, and they spent 13% more time in their optimal blood sugar window.

Still, the success of a similar technique in Shelton is a sign of hope that an outright cure for diabetes may be coming soon.

When Melton told his family the results, they wept, too.

Wed love to hear from you! If you have a comment about this article or if you have a tip for a future Freethink story, please email us at tips@freethink.com.

View post:
First person cured of type 1 diabetes thanks to stem cells - Freethink

City of Hope to buy Cancer Treatment Centers of America for $390M – Modern Healthcare

City of Hope, a prominent not-for-profit cancer researcher and treatment provider, said Wednesday it plans to buy Cancer Treatment Centers of America.

The deal, expected to close early next year pending regulatory approval, would create a large network of inpatient and outpatient oncology care that would serve an estimated 115,000 patients annually. The definitive agreement holds that Duarte, California-based City of Hope would pay $390 million for CTCA, based in Boca Raton, Florida.

"In Cancer Treatment Centers of America, we found an organization that shares with us that nonnegotiable value of putting patients first, the urgency of eliminating cancer and the commitment to delivering high-quality care," City of Hope CEO Robert Stone said in an interview.

The transaction would unite two cancer specialists with decidedly different backgrounds. City of Hope is among 71 National Cancer Institute-designed cancer centers in the country. It's a distinction the federal agency grants to providers that meet rigorous standards for state-of-the-art research focused on improving cancer prevention, diagnosis and treatment. City of Hope is known as a leading cancer researcher, with more than 450 patent portfolios and 95 active investigator-initiated drugs. The provider also runs a large bone marrow and stem cell transplant program.

Dr. Pat Basu, CTCA's CEO, said in an interview he looks forward to granting CTCA's patients access to City of Hope's clinical trials and bone marrow transplant program, which he said is the best in the country. Together, Basu said he thinks the providers will speed up important milestones in cancer research and treatment outcomes.

"Strategically, this a remarkably complementary fit," he said, noting there is no geographic overlap between the providers.

CTCA is a for-profit company with hospitals and outpatient clinics in three metro areas: Atlanta, Chicago and Phoenix. The company sold its hospitals in Philadelphia and Tulsa, Oklahoma earlier this year and has touted a focus on partnerships with health systems that rely heavily on telehealth.

CTCA spent the decade ending in 2016 operating under a federal injunction that barred the company from making unsubstantiated claims in its advertising. The Federal Trade Commission accused CTCA of making false claims regarding its success rates. CTCA cherry-picked patients based on insurance coverage and overhyped the success of its treatments, according to a 2013 Reuters investigation.

"I'm not concerned," Stone said when asked about CTCA's reputation. "I focus more on, frankly: What is it the cancer patients want? Cancer patients want timely access to doctors focused on treating their type of cancer."

City of Hope performed thorough due diligence into CTCA, and Stone said he personally visited the company's facilities in Atlanta and Phoenix. Stone's team emerged convinced that the two companies share the same values, Stone said.

Once the combination is official, City of Hope said it plans to transform CTCA into a not-for-profit organization. Basu will remain CEO of CTCA and will report to Stone. Stone said his team hasn't decided whether they'll pursue NCI designation for CTCA.

The broader goal behind the deal is to make cancer care available to more people, Stone said. Eighty percent of cancer care is currently delivered in community settings, but there's a widening gap between those who get access and those who don't, he said. The combined company would have 575 physicians and more than 11,000 employees across five states.

The deal would expand City of Hope's geographic reach. Its 36 care sites are currently limited to Southern California, in addition to a genomics institute it recently acquired in Phoenix.

Both providers partner directly with employers to offer workers cancer information and support. To that end, City of Hope launched its AccessHope program in 2019, and it now includes 17 Fortune 500 companies.

City of Hope posted a 2.7% operating margin in the nine months ended June 30, up from 0% in the prior-year period. Significant investment income pushed its excess margin to 27% in the 2021 period, when it made almost $700 million on about $2.6 billion in revenue.

As a private, for-profit company, CTCA is not required to disclose information on its financial performance.

Rumors have swirled about a potential CTCA sale since a 2020 report that the company was considering a private equity buy-out. Basu acknowledged there were other potential partners that expressed interest, but said City of Hope is more aligned with CTCA's mission and strategy.

Wednesday's news follows other deal action in the cancer treatment space. Last month, the first publicly traded oncology specialist debuted on the stock market following its merger with a special purpose acquisition company. The Oncology Institute, headquartered in the Los Angeles area, has 50 offices in four states and touts a value-based model of oncology care.

While City of Hope brings cutting-edge research and clinical trials to the table, Basu said CTCA brings a national oncology footprint and a recognizable brand.

"Ultimately I think this is tremendous for patients, it's tremendous for our collective organizations and outstanding for our employees on both sides," he said.

Read more here:
City of Hope to buy Cancer Treatment Centers of America for $390M - Modern Healthcare

The lung game: is hyperbaric oxygen therapy any good? – Financial Times

We typically breathe 25,000 times aday. And were right to be worried about the quality of the air were inhaling. Weve long been concerned about pollution in citiesand Covid has made us focus ever more closely on whats in the air. But is there anywhere or anything we can breathe with impunity? Widely used by athletes, hyperbaric oxygen therapy is linked to benefits ranging from wound healing and long Covid recovery, to improved immunity andbrain function, andeven cellular youth. Footballers Mohamed Salah and Cristiano Ronaldo are fans, as are Michael Phelps and LeBron James and Justin Bieber. Soshould we all sign up?

In HBOT a patient breathes 100 per cent oxygen inapressurised chamber, says Dr Gary Smerdon, CEO ofDDRC Healthcare, a UK-based medical charity that researches diving diseases and provides hyperbaric treatment. The pressure causes the oxygen to dissolve into your blood plasma, he explains; it thereby drives 1,200per cent more oxygen into circulation. A typical solo chamber is a cylindrical pod a bit bigger than an old-school sunbed; its a comfortable enough experience, beyond a slight ear-popping, though not one for the claustrophobic.

Claimed benefits include a lowering of inflammation, aboost in the production of energy in cells throughout the body (via the ATP molecule), an eightfold increase instem-cell circulation (key for repair), enhanced immune function and the formation of new blood vessels. But who derives most from the treatment? Thats controversial. The US Food and Drug Administration and the European Committee of Hyperbaric Medicine have approved 13 conditions for treatment, such as decompression sickness (aka the bends) and non-healing wounds. DDRC Healthcare also treats certain off-label conditions, such asinjuries in professional rugby players. With HBOT, damaged ligaments heal with a more flexiblecollagen, says Smerdon. Some of the UKs leading chambers are designed for racehorses. Given that thebest results start after 20 to 80 hours worth of treatments (which each cost 250), then, says Smerdon, If you are only a weekend warrior, I would say the gainsare too marginal to be worth it.

When it comes to treating long covid, Smerdon says initial findings show promise, but regarding conditions such as ME or fatigue, or using HBOT as an anti-ageing, pro-health hack, he is cautious: Caveat emptor. It may help, but there is no clearly defined evidence. At the same time, he shrugs, getting hard data is challenging, because running the trials is difficult and really expensive. While all the doctors I speak to concur is that HBOT should be done under proper medical supervision (contraindications include certain lung issues) and not simply, says Smerdon, by some high-street beautician, a growing number of unregulated chambersare appearing in the UK.

Do your research and go in with your eyes open

Dr Nur Ozyilmaz is a paediatric consultant who has worked at Kings College Hospital and Great Ormond Street. Her belief in integrative medicine (combining conventional and complementary therapies) has led her to found Numa, a sleek, white hyperbaric centre off Bond Street in London. Each patient is assessed to seeifthey would benefit from treatment; they can present with anything from brain injury to inflammatory bowel disease, and Ozyilmaz has also seen so-called biohackers seeking optimised health and enhanced performance: More and more young City workers come wanting to perform better at work, and often also in sports. Typically they have 20 sessions close together (a 90-minute treatment is 240), then two a week. Iused to discourage them, saying there is no evidence for this kind of approach. It could all be placebo, but they swear it improves their energy levels, sleep and exercise capacity.

Far more patients come with a history of concussion, which has left them with issues such as hormonal imbalances or fatigue, she continues. I am passionate about treating them, as we see such good results. We also see patients with brain fog associated with long Covid, most of whom start reporting improvements from their first few sessions.

Numa will also administer HBOT to older CEOs hoping to sharpen their thinking. This autumn has seen a fresh flurry of interest around HBOT and dementia, with new research concluding it offers multifaceted neuro-protective effects that improve memory and brain function by boosting blood flow and slowing the growth of amyloid plaques in the brain, thought to be connected to Alzheimers. This builds on other studies, such as one that found HBOT induced cognitive enhancements... including information-processing speed and executive functions.

However, says Dr Gary Toups, head of hyperbaric medicine at the Mayo Clinic in Rochester, Minnesota, Ive not seen any significant effect on cognition in patients treated with HBOT. Along with Smerdon, he says more research is needed to investigate whether HBOT may slow down cellular ageing: a widely publicised Israeli study suggested it might, finding that the length of telomeres (the protective caps over the end of our chromosomes, which diminish as we age) increased by more than 20 per cent over a 60-day treatment, and damaging, senescent zombie cells decreased by up to 37 per cent. So far, he says, it is only a single study, the importance of which has yet to be determined.

Do your research and go in with your eyes open, says Smerdon. In off-label treatments, some people get excellent results; for others theres no effect. Ozyilmaz is more optimistic. What excites me about HBOT is the huge potential it offers without drugs or side effects, she says. It looks to a future of medicine where we can harness our bodys own ability to repair and regenerate, to support ourselves to optimal health.

Original post:
The lung game: is hyperbaric oxygen therapy any good? - Financial Times

Cell Culture Media Market is predicted to grow from US$ 2.6 Bn in 2020 to over US$ 5.6 Bn by 2031 – PRNewswire

Demand for cell culture media is increasing with rising production of biopharmaceuticals. Biopharmaceutical drugs are structurally similar to human compounds. This similarity in structure gives biopharmaceuticals the ability to cure diseases rather than only treat the symptoms. Also, biopharmaceuticals have fewer side effects because of their specificity, unlike conventional drugs that affect multiple systems. Biopharma is helping doctors in treating various diseases such as diabetes and cancer, because it allows clinicians to give specialized treatment to the specific medical problems of each patient.

With increasing demand for regenerative medicines, sale of cell culture media also increases. It is because regenerative medicine is that branch of medicine that develops methods to regrow, heal or replace injured or unhealthy cells, organs, and tissues.

Request for sample PDF of report: https://www.persistencemarketresearch.com/samples/31338

Key Takeaways from Market Study

"Increasing production of antibodies for treatment of diseases and rising prevalence of cancer are expected to drive demand of cell culture media over the decade," says a Persistence Market Research analyst.

Get Full TOC of the report: https://www.persistencemarketresearch.com/market-research/cell-culture-media-market/toc

Who is Winning?

Some of the chief manufacturers of cell culture media are focusing on product launches, collaborations, and acquisitions for global expansion objectives, thereby enhancing their market presence.

Key market players covered in this research include GE Healthcare, Thermo Fisher Scientific, Merck KGaA, Lonza, Corning Incorporated, Irvine Scientific, STEMCELL Technologies Inc., and PAN Biotech.

Get Full access of report: https://www.persistencemarketresearch.com/checkout/31338

Want More Valuable Insights?

Persistence Market Research brings the comprehensive research report on forecasted revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2016 to 2031. The global cell culture media Market is segmented in detail to cover every aspect of the market and present a complete market intelligence approach to the reader.

The study provides compelling insights into the cell culture media market. The market is segmented into five parts based on product (serum containing media, serum-free media, protein free media, and chemically defined media) based on application (cancer research, biopharmaceuticals, regenerative medicine & tissue engineering, stem cell technologies, and others) based on the end user (biopharmaceutical companies, clinical research organizations, and academic research centers), and across seven major regions.

Related Reports:

o Cell Tissue Culture Supplies Marketo Stem Cell Therapy Marketo 3D Cell Cultures Market

About Persistence Market Research:

Persistence Market Research (PMR), as a 3rd-party research organization, does operate through an exclusive amalgamation of market research and data analytics for helping businesses ride high, irrespective of the turbulence faced on the account of financial/natural crunches.

Overview:

Persistence Market Research is always way ahead of its time. In other words, it tables market solutions by stepping into the companies'/clients' shoes much before they themselves have a sneak pick into the market. The pro-active approach followed by experts at Persistence Market Research helps companies/clients lay their hands on techno-commercial insights beforehand, so that the subsequent course of action could be simplified on their part.

ContactRajendra Singh Persistence Market Research U.S. Sales Office: 305 Broadway, 7th Floor New York City, NY 10007 +1-646-568-7751 United States USA - Canada Toll-Free: 800-961-0353 Email: [emailprotected] Visit Our Website:https://www.persistencemarketresearch.com

SOURCE Persistence Market Research Pvt. Ltd.

Go here to see the original:
Cell Culture Media Market is predicted to grow from US$ 2.6 Bn in 2020 to over US$ 5.6 Bn by 2031 - PRNewswire

It is imperative to reduce the cost of cancer treatment: Ramesh Ramadurai, MD, 3M India – ETHealthworld.com

Shahid Akhter, editor, ETHealthworld, spoke to Ramesh Ramadurai, MD, 3M India, to know more 3M collaborations that can improve and impact cancer care, besides cutting down on the costs in a big way.

How has the technological and infrastructural facilities impacted Bone Marrow Transplantation in India ? Every year nearly 20,000 Indian patients, including many children, who suffer from blood and solid cancers require bone marrow transplantation (BMT). However, only 2,000 of these patients are fortunate enough to receive this therapy, as the cost of bone marrow transplantation can vary from INR 10 Lakhs to 30 Lakhs. It is imperative to reduce the cost of cancer treatment while maintaining a stringent focus on sterilization and quality. It is indeed the need of the hour for us to address this issue.

What are the various technological advancement required for the better functioning of the facilities?Despite the increasing demand for bone marrow transplantation, the number of bone marrow doners in India is astonishingly low. India conducts stem cell transplant procedure for approximately 2,000 every year, while around 80,000 to 100,000 annual transplants are required to tackle the burden of blood cancers and fatal blood disorders. Finding a matching donor is very difficult. This option is exercised only after the alternative options have failed.

India has only about 400,000 donors registered on the bone marrow registry. Chances of finding a donor match are as low as 10% to 15% compared to the West where the chances of matching are as high as 60% to 70% due to higher rates of donations.

What are the major and significant developments in treating bone marrow cancer in the country? A bone marrow registry collects information on individuals willing and able to donate bone marrow and gathers the donor information into a database. In India, organisations like Datri are helping to create a pool of donors to help people who do not have blood-related donors by finding an unrelated match for life-saving treatment.

Infusion of a memory cell is another advancement. This involves taking out the cells, sorting the good cells and the memory cells or the fighting cells, which can fight infections, sorting them out, capturing them and putting them back into the body after giving the requisite chemotherapy. This is also called T-cell depletion with memory cell infusion. It is now available in India and is affordable.

Through this partnership with United Way Bengaluru and Sri Shankara Cancer Hospital and Research Centre (SSCHRC), how does 3M aim to foster accessibility for people from different sections of the society in treating cancer. 3M India was brought into the SSCHRC family through United Way of Bengaluru, and this is our second round of engagement with the hospital. Last year, 3M India had donated equipment for cancer research and diagnostics like the Sanger sequencer and QPCR, made enhancements to the childrens play area at the long-stay Lakshmi Childrens center with child-friendly wall graphics, and provided kitchen utensils and cooking counters for the resident families of paediatric cancer patients.

We have donated several critical equipments for the research labs which contribute to the successful treatment of the BMT patients. As on date the BMT unit at SSCHRC has treated and discharged 5 patients and currently 4 are undergoing treatment. This wing of the hospital is accessible by few staff nurses and specialists like Dr K N Nataraj who is the Chief of Adult and Paediatric Haematology at the hospital. For a successful bone marrow transplantation, there are several requisites, some of which include, successful donor matching, extremely technique-sensitive harvesting and transplantation processes and robust infection control. With this essential, life-saving equipment, the cost of the treatment will reduce to approximately 50% (between Rs 8-12 Lacs as against the actual cost of Rs 15- 30 lacs) and help the hospital treat many more cancer patients.

How do 3M India and Sri Shankara Hospital plan to take this initiative ahead in the future for the growth and enhancement of bone marrow transplantation in the facility? It is matter of pride for 3M India and United Way of Bengaluru that we are associated with SSCHRC, an institution at the forefront of providing comprehensive cancer treatment to the needy, through CSR interventions.

By complying with the Foundation for the Accreditation of Cellular Therapy (FACT) Guidelines, the BMT Centre will be a one-of-a-kind medical facility where people of all economic status can receive treatment. Being a growing facility, the hospital is committed to continuing its responsibility towards expansion of multiple hospital beds and medical care. We are inspired by the commitment of the doctors and Sri Shankara Board of Trustees, led by Dr. B.S. Srinath and other dedicated professionals who developed a multifaceted approach to establishment a state of the art, affordable cancer hospital that is accessible to all irrespective of caste, creed, religion, gender or socioeconomic status.

Read the original:
It is imperative to reduce the cost of cancer treatment: Ramesh Ramadurai, MD, 3M India - ETHealthworld.com

COVID: How bad is the omicron variant? Q&A on what new research is telling us – The Denver Post

The new omicron variant is spreading fast. But research is beginning to catch up.

Because an early case was detected in San Francisco, local scientists have quickly started growing the virus in high-security labs at UC San Francisco, UC Berkeley and Stanford.

Using cell cultures, theyll soon learn how readily it transmits, whether it can dodge our defenses and outcompete delta. In mice, theyll study whether it produces illness that is severe or mild.

In one or two weeks, we will have a much clearer picture of what this variant is going to do to us, said Dr. Melanie Ott of UC San Franciscos Gladstone Institute of Virology and Immunology.

Meanwhile, South Africa studies have begun to offer a real-world glimpse of how much risk omicron poses.

The extent to which omicrons sudden spread is caused by immune evasion or more contagiousness or both is yet unclear. But as the variant expands into 17 U.S. states and at least 45 nations worldwide, heres what were learning:

Q: Is omicron more or less dangerous than delta?

A: A new small study suggests that omicron may cause less severe illness than previous variants like delta.

The best indicator of disease severity is the in-hospital death rate. A report this weekend identified 10 omicron-linked hospital deaths at two South African hospitals, representing about 6% of 166 COVID-related admissions. This compared to a 17% death rate at the hospitals among COVID-19 patients during previous waves of infections. However, this time it wasnt just elders who died; four of the deaths were in adults ages 26 to 36.

The same hospital said that the majority of COVID patients did not need extra oxygen, and far fewer were so sick that they were admitted to the ICU. Most discovered they were infected only after being admitted to the hospital for other health reasons. The average hospital stay was only 2.8 days, down from 8.5 days during infection with other variants.

Most of these patients were unvaccinated, although there were some vaccinated admissions, as well.

Can this be generalized given the younger population in South Africa, with very extensive prior COVID? Thats an uncertainty that will remain until we see much larger numbers of infections in older people.

South African Medical Research Council

Q: Whats the latest guess about how infectious it is?

A: In South Africa, about 3 to 3.5 new omicron infections are estimated to stem from a single case. In contrast, the reproductive rate of delta in South Africa and the U.S. was about 1.5.

If omicrons reproductive rate continues at around 3, this indicates a much larger threat, in terms of case counts, than delta. The size of the wave depends on the susceptible population.

Trevor Bedford, Fred Hutchinson Cancer Research Center in Seattle

Q: Will omicron overtake delta?

A: In South Africa, omicron has surpassed delta as the dominant strain. But delta was on the wane there, so omicron had an open field to run in. Omicron did not have to push delta out.

What we dont know is how well omicron will compete in an environment thats 99.9% delta, such as California.

Dr. Warner Greene, Director of Gladstone Institute of Virology and Immunology, UCSF

Q: If it outcompetes delta, and its milder, isnt that good news?

A: It would be great if omicron is always a mild virus. But we dont know that yet. It will take a month or so to learn the virulence of this variant, and whether it will replace delta.

Dr. Warner Greene

Q: Will my previous infection protect me?

A: Perhaps not. South African doctors are seeing an uptick in reinfections among people who tested positive for the virus at least 90 days earlier, suggesting that immunity acquired through natural infection is not fully protective.

Omicron is three times more likely to cause reinfection compared to delta, according to a Dec. 2 paper.

Juliet Pulliam, director of the South African Centre for Epidemiological Modelling and Analysis, Stellenbosch University

Q: Are vaccines protective against infection?

A: We dont yet know. In infected patients in one very small South African study, more than half were considered fully vaccinated, with two shots.

But its unclear how much time had passed since their inoculation. If it was more than six months, their antibody levels had waned.

These patients hadnt gotten boosters. Boosting creates a huge increase in antibodies much more than what is achieved after the second vaccine dose. Thats what is leading vaccinologists to hope that even if antibody levels start to decline, protection will last longer. Its starting at a much higher level.

Dr. Warner Greene

Q: How long will it take to design omicron-specific vaccines?

A: Vaccine makers Pfizer and Moderna say they can get one ready within 100 days. Making a new mRNA vaccinewill involve generating a new genetic sequence, based on omicron, and encapsulating it in a fatty substance such as a lipid.

This autumn, the vaccine companies have been doing dry runs, practicing all aspects of executing a strain change the preclinical research, the manufacturing, the clinical testing and the regulatory submissions so they are ready to respond quickly.

Journal Nature

Q: Then will we have to wait for new clinical trials and FDA approval?

A: The FDA told the Wall Street Journal that it is already in conversations about streamlining authorization for revamped vaccines. Agency officials have met with vaccine makers and are working to set guidelines for the type of data that will be needed to swiftly evaluate the safety and efficacy of changes to current vaccines.

Wall Street Journal

Q: Should omicron change how we celebrate the holidays?

A: Its probably best to avoid international travel. Its far better to fly domestically than take a long haul flight to Europe, Asia or Africa. And be careful about where you fly domestically. Dont fly into a hot zone.

But experts like Dr. Greene say their perspective is so different this December versus last year. My family and I are vaccinated, he said. I do not believe that Im going to die of this coronavirus. I dont believe my family will die of this coronavirus.

Yes, I may get infected. I might be sick for awhile. But I am really confident that Im not going to die. And that just changes my whole perspective. Were in such a better place.

Dr. Warner Greene

Join our Facebook group for the latest updates on coronavirus in Colorado.

See the original post here:
COVID: How bad is the omicron variant? Q&A on what new research is telling us - The Denver Post

The most searched songs on Google in 2021 – Market Research Telecast

Every year, Google reveal what they were Searches that were highlighted in the last 12 months, making certain items a trend. For example, the company can show which films were most investigated by viewers, as well as series or even the actors and celebrities who stood out for a film or even a scandal during the year. Therefore, here we tell you what they were the most searched songs in 2021.

The song MAP refers to the combination between the first syllables of the words mom and dad. This theme had a launch, through Sony Music, in May 2021 and was performed by the Filipino boy band SB19. Today they have 1,190,820 monthly listeners through Spotify and there are more and more followers of the group formed by Pablo, Stell, Josh, Ken and Justin.

Performed by country music singer Walker Hayes, the simple Fancy Like was one of the most searched on Google in 2021. This song was released in August of this year on the occasion of the EP Country Stuff via Monument Records Nashville. Months later, in September, the American published a remix that had the participation of Kesha and that further triggered the song.

The American rapper Lil Nas X He led all the 2021 rankings with his songs. For this reason, their presence was evident in the most wanted during the year. Your song Industry Baby, In collaboration with Jack Harlow, it was very successful. Its launch was in July through Columbia Records and featured the co-production of Kanye West, making the single proposal even more attractive.

Another of the undisputed hits of Lil Nas X this year it was MONTERO (Call Me By Your Name). Also through Columbia Records, was released in March 2021. This was the lead single from his first studio album Montero, which was finally released in full in September of this year. It was written by himself with Take a Daytrip, Omer Fedi and Roy Lorenzo.

If it is about female voices, Olivia rodrigo was the main one of 2021. The actress and singer who rose to fame with High School Musical: The Musical: The Series, dazzled with his album Sour. However, long before publication, she distinguished herself with her single drivers license, written by her with Dan Nigro. Although it debuted in January of this year, 12 months later it is still the most searched song on Google.

If you have a Telegram account, just click on the following button.

But if you dont have a profile on the platform yet, you can download it from the Apple Store or the Google Store, depending on your cell phones operating system. Once inside the application, in the search engine put SpoilerBV and there you can give us subscribe to be aware of all the news.

Disclaimer: This article is generated from the feed and not edited by our team.

Read the original here:
The most searched songs on Google in 2021 - Market Research Telecast

SOTIO Announces Clinical Collaboration with MSD to Evaluate IL-15 Superagonist, SOT101, in Combination with KEYTRUDA® (pembrolizumab) in Patients…

PRAGUE, Czech Republic, Dec. 08, 2021 (GLOBE NEWSWIRE) -- SOTIO Biotech, a clinical stage immuno-oncology company owned by PPF Group, announced today that it has entered into a clinical trial collaboration and supply agreement with MSD, a tradename of Merck & Co., Inc., Kenilworth, NJ., through its subsidiaries, to evaluate the combination of SOT101, SOTIO’s IL-15 superagonist, and MSD’s KEYTRUDA® (pembrolizumab) in patients with selected advanced/refractory solid tumors in the phase 2 AURELIO-04 study.

See more here:
SOTIO Announces Clinical Collaboration with MSD to Evaluate IL-15 Superagonist, SOT101, in Combination with KEYTRUDA® (pembrolizumab) in Patients...

Celldex Announces First Patient Dosed in Phase 1 Study of CDX-0159 in Prurigo Nodularis

HAMPTON, N.J., Dec. 08, 2021 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced that the first patient has been dosed in a Phase 1 study of CDX-0159 for the treatment of prurigo nodularis (PN). CDX-0159 is a humanized monoclonal antibody that specifically binds the receptor tyrosine kinase KIT with high specificity and potently inhibits its activity. PN is a chronic skin disease that causes hard, intensely itchy lumps/nodules to form on the skin. The itching (pruritus) can be intense, causing people to scratch themselves to the point of bleeding or pain, which can form lesions and perpetuate the disease cycle.

Read more here:
Celldex Announces First Patient Dosed in Phase 1 Study of CDX-0159 in Prurigo Nodularis

Sugarmade Provides Corporate Update as Nug Avenue Sees Accelerating Growth Ahead of Further Expansion

NEW YORK, NY, Dec. 08, 2021 (GLOBE NEWSWIRE) -- Sugarmade, Inc. (OTC Pink: SGMD) ("Sugarmade", "SGMD" or the "Company") an emerging leader in the vertically integrated California cannabis marketplace, is pleased to provide this update to its shareholders as the Company moves toward new growth initiatives while continuing to expand organically within the framework of its primary operating vision.

Continued here:
Sugarmade Provides Corporate Update as Nug Avenue Sees Accelerating Growth Ahead of Further Expansion